Comparative Pharmacology
Head-to-head clinical analysis: MAXALT versus TRIAD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXALT versus TRIAD.
MAXALT vs TRIAD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve signaling.
Triad is a combination of three antibiotics: amoxicillin, metronidazole, and tetracycline. Amoxicillin inhibits bacterial cell wall synthesis. Metronidazole disrupts bacterial DNA synthesis via reduction to toxic metabolites. Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
5 mg or 10 mg orally at onset of migraine; maximum 30 mg in 24 hours (two doses with at least 2 hours between them).
Not applicable. TRIAD is not a recognized drug; no standard dosing exists.
None Documented
None Documented
2-3 hours in plasma; clinical effect correlates with distribution to CNS rather than plasma half-life.
Terminal t1/2 = 12–15 hours; prolonged to 24–36 hours in hepatic impairment.
Renal (60% as unchanged drug and metabolites) and fecal (40% primarily as metabolites).
Renal: 30% unchanged; Biliary/fecal: 70% as metabolites.
Category C
Category C
Antimigraine Agent
Antimigraine Agent